Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025

PLUS THERAPEUTICS, INC.

2023-Q3 EPS reported -$3.54

Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.
Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.
Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.
Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.
Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLUS THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: net income $(3.2) million, or $(1.00) per share, EPS $(1.00) per share.

Period: third quarter ended September 30, 2023
Net income: $(3.2) million, or $(1.00) per share
EPS: $(1.00) per share
Result: reported results

Exact text from the filing

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

View on SEC.gov

Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-267200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.